Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Rectal Cancer treatment details. Chemotherapy. Antwerp University Hospital, Edegem, Belgium



Survival: 12.5 months
   
Toxicity Grade: 5
   
Treatments: Chemotherapy
   
Drugs:
Country: Belgium
   
City/State/Province: Edegem
   
Hospital: Antwerp University Hospital
   
Journal: Link
   
Date: 11/2010

Description:
Patients:
This phase III study involved patients with metastatic colorectal cancer who had previously received chemotherapy. Patients were divided into two separate treatment groups. Group A consisted of 541 patients with a median age of 60 years and 59% were male. There were 542 patients in group B, the median age was 62 years, and 62% were male.

Treatment:
Group A was treated with the combination of chemotherapy agents called FOLFIRI (includes fluorouracil, leucovorin, and irinotecan) as well as the biologic therapy called panitumumab, which is a monoclonal antibody that blocks EGFR, a protein involved in cancer cell growth. Group B was treated with FOLFIRI only.

Toxicities:
For group A, treatment-related deaths due to diarrhea and intestinal obstruction were reported (toxicity grade 5). Skin reactions, GI tract inflammation (mucositis), and neutropenia of grade 3-4 were also reported in this group.

Treatment-related deaths due to sepsis and heart failure were reported for group B. Grade 3-4 neutropenia and diarrhea were also reported.

Results:
The median progression-free survival for groups A and B was 5.9 and 3.9 months, respectively. The median overall survival was 14.5 months for group A and 12.5 months for group B.

Support:
This study was supported by Amgen, makers of Vectibix, the trade name for panitumumab.

Correspondence: Dr. Marc Peeters; email: Marc.Peeters@uza.be

E-mail to a Friend Email Physician More Information